For decades, wound healing has been dominated by passive dressings and fragile biologics. ZegeneX takes a fundamentally different path — a thermostable small molecule that activates upstream regulators of tissue repair to drive faster, deeper, more reliable healing.
Our small molecule acts on a proprietary upstream regulator of keratinocyte proliferation and angiogenesis. Instead of supplementing one growth factor, it orchestrates the body’s entire regenerative cascade.
The shelf-stable topical formulation crosses the hostile wound microenvironment biofilm, necrotic tissue and exudate — to reach viable cells at the wound bed.
The compound engages a proprietary upstream signalling target, unlocking the regenerative program in keratinocytes and endothelial cells.
Keratinocyte migration, angiogenesis and granulation tissue formation are simultaneously accelerated — without triggering the negative feedback loops that limit growth-factor biologics.
Re-epithelialization completes, collagen architecture is restored, and the wound is closed — faster, stronger, with fewer recurrences.
Compared head-to-head with the only FDA-approved growth-factor therapy and standard cell-based products, ZegeneX delivers comparable or superior outcomes — at a fraction of the operational cost.
| Attribute | Growth-Factor Biologics e.g., becaplermin / Regranex | ZegeneX (Zegen-X5) |
|---|---|---|
| Mechanism | Single growth factor; subject to feedback inhibition | Novel upstream regulator — amplifies multiple endogenous pathways |
| Storage | Refrigerated; hours of life once reconstituted | Ambient (25°C) — 24+ months stable |
| Manufacturing | Biologic process; complex, costly | Scalable small-molecule chemistry |
| Cost per course | Thousands of dollars | Dramatically lower projected COGS |
| Deployment | Cold-chain dependent; urban / advanced settings only | Universal — clinics, military, rural, disaster, home |
| Black-box warning | Yes (Regranex) | No adverse events observed in preclinical tox |
A complete IND-enabling preclinical package — independently designed, executed, and analyzed.
Existing growth-factor biologics like becaplermin require refrigeration and have hours-long usable life once reconstituted — unusable in rural, military or emergency contexts.
Wound closure accelerated by 42% vs. control at Day 10. Histology confirmed superior re-epithelialization and collagen density, comparable to positive control (PDGF-BB).
~90% closure in diabetic wound model by Day 10 — validating both mechanism and formulation under impaired-healing conditions.
Non-GLP single-dose study established NOAEL. No systemic toxicity, no significant local irritation observed.
>95% purity maintained at 25°C/60% RH for 24 months and 40°C/75% RH for 6 months. Unmatched by any approved biologic.
Favorable topical absorption; minimal systemic exposure; no accumulation in key organs — supporting a clean safety profile.
That’s not a marketing slogan. That’s the preclinical median, replicated across studies and species. And every day saved on the wound bed is a day less of infection risk, a day less of pain, and a day closer to walking again.
Compound integrity retained after 6 months at 25°C / 60% RH — fully meeting ICH Q1A long-term stability criteria without refrigeration.
Every approved biologic in wound care is shackled to the cold chain. ZegeneX isn’t. That means we can stockpile for military trauma, ship to rural clinics in sub-Saharan Africa, deploy in disaster response, and sit on a patient’s bedside table for months without losing potency.
Filed and prosecuted in collaboration with a leading life-sciences patent firm — maximizing protection across the world’s key markets.
Full US patent covering the compound and analogs. Projected exclusivity to 2044+.
US provisional filed — covering the shelf-stable topical-gel formulation that defines our deployment advantage.
US provisional filed — covering chronic and complex wound-healing indications including DFUs, VLUs, pressure injuries.
Manufacturing process and proprietary analytical methods maintained as trade secrets — adding a second layer of defensibility.
Qualified strategic partners and accredited investors can request our complete preclinical data package and IP portfolio under a mutual NDA.
A preclinical-stage biopharmaceutical company developing first-in-class, shelf-stable wound healing therapeutics — making advanced care accessible everywhere.
